-
Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients
Tuesday, February 15, 2022 - 1:50pm | 306Read More...Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers...
-
BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer
Tuesday, February 15, 2022 - 8:48am | 364Read More...BioXcel Therapeutics Inc (NASDAQ: BTAI) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Results will be highlighted in two...
-
Medivation Up As Triple M&A Interest Rumor Circulates
Tuesday, March 22, 2016 - 11:47am | 292Read More...Medivation Inc (NASDAQ: MDVN) is up roughly 2 percent on Tuesday, trading at $37.68. According to the UK's financial outlet This Is Money, Medivation may be courting suitors. Among the names that have begun circulating as interested parties are AstraZeneca plc (ADR) (NYSE: AZN), Sanofi SA (ADR) (...
